Circulating Chemerin Levels are Increased in First-Degree Relatives of Type 2 Diabetic Patients

Zhuang, Xiaoming; Sun, Fan; Chen, S H; Liu, Y T; Liu, W; Li, X B; Pan, Zhenhong; Lou, Nengjun

doi:10.7754/clin.lab.2013.130503

Cited by 6 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Decreased levels of omentin-1 were detected in patients with impaired glucose tolerance and newly diagnosed, untreated T2DM [107]. Its levels are decreased in obese and overweight subjects and decrease when obese subjects lose weight [108,109]. Omentin inhibits osteoblast differentiation and vascular smooth muscle cell calcification.…”

Section: Obesity Adipokines and Chronic Complicationsmentioning

confidence: 99%

Adipokines and Obesity. Potential Link to Metabolic Disorders and Chronic Complications

Zorena

Jachimowicz-Duda²,

Ślęzak

et al. 2020

IJMS

259

196

View full text Add to dashboard Cite

The World Health Organization (WHO) has recognized obesity as one of the top ten threats to human health. It is estimated that the number of obese and overweight people worldwide exceeds the number of those who are undernourished. Obesity is not only a state of abnormally increased adipose tissue in the body, but also of increased release of biologically active adipokines. Adipokines released into the circulating blood, due to their specific receptors on the surface of target cells, act as classic hormones affecting the metabolism of tissues and organs. What is more, adipokines and cytokines may decrease the insulin sensitivity of tissues and induce inflammation and development of chronic complications. Certainly, it can be stated that in an era of a global obesity pandemic, adipokines may gain more and more importance as regards their use in the diagnostic evaluation and treatment of diseases. An extensive search for materials on the role of white, brown and perivascular fatty tissue and obesity-related metabolic and chronic complications was conducted online using PubMed, the Cochrane database and Embase.

show abstract

Section: Obesity Adipokines and Chronic Complicationsmentioning

confidence: 99%

Adipokines and Obesity. Potential Link to Metabolic Disorders and Chronic Complications

Zorena

Jachimowicz-Duda²,

Ślęzak

et al. 2020

IJMS

259

196

View full text Add to dashboard Cite

show abstract

“…As an adipokine chemerin is released by adipocytes [23], but also hepatocytes produce considerable levels of the protein [24]. Serum chemerin is increased in overweight/obesity and correlations with obesity associated traits, like low grade inflammation, blood pressure, and insulin resistance, were identified in some but not all of the patient cohorts studied [1,25,26,27,28,29,30]. Hence, the associations of systemic chemerin levels with the metabolic syndrome are not fully resolved [1,25,26,27,28,29,30].…”

Section: Introductionmentioning

confidence: 99%

Chemerin Isoforms and Activity in Obesity

Buechler

Feder

Haberl

et al. 2019

IJMS

120

156

View full text Add to dashboard Cite

Overweight and adiposity are risk factors for several diseases, like type 2 diabetes and cancer. White adipose tissue is a major source for adipokines, comprising a diverse group of proteins exerting various functions. Chemerin is one of these proteins whose systemic levels are increased in obesity. Chemerin is involved in different physiological and pathophysiological processes and it regulates adipogenesis, insulin sensitivity, and immune response, suggesting a vital role in metabolic health. The majority of serum chemerin is biologically inert. Different proteases are involved in the C-terminal processing of chemerin and generate diverse isoforms that vary in their activity. Distribution of chemerin variants was analyzed in adipose tissues and plasma of lean and obese humans and mice. The Tango bioassay, which is suitable to monitor the activation of the beta-arrestin 2 pathway, was used to determine the ex-vivo activation of chemerin receptors by systemic chemerin. Further, the expression of the chemerin receptors was analyzed in adipose tissue, liver, and skeletal muscle. Present investigations assume that increased systemic chemerin in human obesity is not accompanied by higher biologic activity. More research is needed to fully understand the pathways that control chemerin processing and chemerin signaling.

show abstract

“…insulin resistance is increased in the metabolic syndrome and correlates with systemic chemerin [34]. A recent study analyzed chemerin in firstdegree relatives of type 2 diabetic patients and found that triglycerides and homeostatic model assessment insulin resistance (HOMA-IR) are independent risk factors that influence systemic chemerin [35].…”

Section: Serum Chemerin and Metabolic Syndromementioning

confidence: 99%

Chemerin in Liver Diseases

2014

Endocrinol Metab Synd

View full text Add to dashboard Cite

Chemerin is a chemoattractant protein and moreover has a role in adipogenesis, angiogenesis and glucose homeostasis. Chemerin is primarily synthesized and secreted by adipocytes and hepatocytes. Chemerin receptors chemokine-like receptor 1 (CMKLR1), G-protein coupled receptor 1 (GPR1) and CC-motif chemokine receptorlike 2 (CCRL2) are all expressed in the liver suggesting that chemerin may be relevant in liver physiology and pathophysiology. Non-alcoholic fatty liver disease (NAFLD) is associated with obesity and is the most common cause of chronic liver injury. NAFLD and chronic hepatitis C virus infection are risk factors for hepatocellular carcinoma. Hepatic and serum chemerin have been analyzed in human and rodent NAFLD, in patients with chronic hepatitis C and patients with hepatocellular carcinoma. Chemerin, GPR1 and CMKLR1 deficient mice have been used to elucidate the role of these proteins in body weight gain and glucose homeostasis. The regulation of chemerin and CMKLR1 by adipokines, hormones and cytokines relevant in liver diseases has been studied in hepatocytes. The data published so far are briefly summarized herein. Current experimental findings do not provide evidence for a crucial role of chemerin in chronic liver diseases and further research is needed to evaluate a possible protective function of this protein in hepatocellular carcinoma.

show abstract

Circulating Chemerin Levels are Increased in First-Degree Relatives of Type 2 Diabetic Patients

Cited by 6 publications

References 0 publications

Adipokines and Obesity. Potential Link to Metabolic Disorders and Chronic Complications

Adipokines and Obesity. Potential Link to Metabolic Disorders and Chronic Complications

Chemerin Isoforms and Activity in Obesity

Chemerin in Liver Diseases

Contact Info

Product

Resources

About